• Neuroligin 1 Proteolysis Sustains Social Memory

  2026-08-15

  Liu et al. show that social interaction triggers α- and γ-secretase processing of Neuroligin 1 in the ventral hippocampus, producing an intracellular NLG1-CTD fragment required for social memory maintenance. The study links this proteolytic signal to PDZ-dependent cofilin regulation, dendritic spine remodeling, and rescue of memory-maintenance deficits.

• METTL14–SMN Methylation Controls m6A Homeostasis

  2026-08-14

  The reference study identifies SMN as an arginine methylation-dependent interaction partner of METTL14, connecting spinal muscular atrophy mutations with defective m6A deposition on DNA repair transcripts. Its cellular and mouse models show that this pathway influences genome stability, DNA-damage sensitivity, embryonic development, and hematopoiesis, while also highlighting important limits for disease-model interpretation.

• EGTA for Calcium Signaling: Applied Workflows

  2026-08-14

  EGTA, or egtazic acid, gives researchers a practical way to test whether extracellular calcium drives inflammation, cytotoxicity, or apoptosis. This guide translates the Talin1–Piezo1–YAP findings into controlled endothelial assays while extending the same chelation logic to neuroprotection and calcium-dependent cell injury models.

• v-Agatoxin-IVA: N-Type Calcium Channel Blockade

  2026-08-13

  Sidach and Mintz showed that v-Agatoxin-IVA is not exclusively a high-affinity P-type calcium channel blocker: at higher concentrations, it also weakly inhibits neuronal N-type currents through a voltage-dependent mechanism. The findings refine toxin-based channel classification and caution against using micromolar v-Agatoxin-IVA as a selective probe for Q-type currents.

• V5 Epitope Tag Peptide: From Tag to Probe

  2026-08-13

  The V5 Epitope Tag Peptide is more than a detection handle: it can anchor a rigorous strategy for interpreting antibody kinetics, assay controls, and recombinant protein measurements. This article connects the GKPIPNPLLGLDST peptide with single-molecule antibody screening and practical workflow design.

• Phenytoin for Myelin Remodeling Research

  2026-08-12

  Phenytoin provides a controllable pharmacological lever for testing how sodium-channel activity influences early myelin swelling, oligodendrocyte survival, and recovery. This workflow combines fresh-solution handling, electrophysiology assay validation, and longitudinal imaging while clearly separating reference-study findings from proposed experimental applications.

• Sulforaphane: Redox and NLRP3 Workflows

  2026-08-12

  Build reproducible Sulforaphane experiments that connect Keap1-Nrf2 signaling, oxidative stress, inflammasome activity, and cancer-related phenotypes. This guide translates recent colitis-model findings into practical cell-based assays, animal-study design, and troubleshooting decisions.

• Drug Response Assays: Viability Versus Cell Death

  2026-08-11

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central practical contribution is a framework for separating proliferative arrest from cell killing and interpreting their distinct proportions and timing in vitro.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-08-11

  FITC-Concanavalin A is a fluorescent lectin conjugate for visualizing accessible α-D-glucose and α-D-mannose residues on cell surfaces, tissues, glycoproteins, and glycolipids. It is intended for defined carbohydrate-binding workflows such as immunofluorescence staining and flow cytometry, not for non-carbohydrate assays or use outside the stated storage and stability conditions.

• PXR Activation, Liver Regeneration, and CYP Activity

  2026-08-10

  A 2024 rat study shows that pharmacological activation of pregnane X receptor (PXR) can enlarge the liver and promote regeneration while increasing the expression and in vivo metabolic activity of CYP3A1/2 and CYP2C6/11. Its cocktail-probe and partial-hepatectomy design helps distinguish structural liver adaptation from functional drug-metabolizing capacity during regeneration.

• Drug Response Measurement in Cancer In Vitro

  2026-08-09

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify how anticancer drugs combine growth inhibition and cell killing. Its central implication is methodological: drug-response studies should measure proliferation arrest and death as related but noninterchangeable processes, while considering their different timing and magnitudes.

• InstaBlue Protein Stain Solution for Antibody Workflows

  2026-08-08

  InstaBlue Protein Stain Solution streamlines antibody-expression QC by revealing protein bands in minutes without fixation, destaining, or hazardous methanol and acetic acid. Its sensitive, mass spectrometry-compatible format helps researchers connect gel-based quality checks with structural and functional studies such as the XG005 antibody-evolution work.

• Ouabain Workflows for Na+/K+-ATPase Research

  2026-08-07

  Build more informative ion-transport experiments with Ouabain, a selective Na+/K+-ATPase inhibitor designed for acute extracellular pump perturbation. This guide connects cell, tissue, and cardiovascular workflows with practical dose selection, orthogonal readouts, and troubleshooting strategies.

• Caspase-3/7 Inhibitor I: Precision in Apoptosis Workflow Des

  2026-08-07

  Caspase-3/7 Inhibitor I empowers researchers to dissect caspase-dependent cell death with high selectivity and workflow flexibility. Its utility spans apoptosis inhibition in complex models, protocol refinement, and troubleshooting, setting a new benchmark for mechanistic studies in cell death modulation.

• Protease Inhibition: Strategic Leverage for Translational Di

  2026-08-06

  This thought-leadership article delivers a mechanistic and strategic roadmap for translational researchers leveraging the DiscoveryProbe™ Protease Inhibitor Library. By synthesizing recent advances in protease biology, high-throughput screening, and experimental validation—anchored by HIV-1 protease autoprocessing and translational oncology studies—we outline actionable protocols, highlight competitive differentiation, and explore the clinical trajectory of protease inhibition. The piece elevates the conversation beyond generic product overviews, articulating new frontiers in workflow integration and precision discovery.

14872 records 1/992 page Next 12345 下5页 Last page